#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13456	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2235	592.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1406	1406	C	790	C,A,T	772,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13456	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2235	592.9	0	HET	.	.	.	C136CGGGGG,CGGGG	.	136	136	C	358	358	C	699	CGGGGG,CGGGG	500,147	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3669	674.7	0	.	n	.	0	T695C	SNP	695	695	T	1039	1039	C	787	C,T	768,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3669	674.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1681	1681	A	810	A,G	796,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3669	674.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2315	2315	C	807	C	791	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3669	674.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2941	2941	T	734	T,C	724,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3669	674.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2389	2389	A	785	A	771	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1770	folP	852	852	100.0	folP.l15.c4.ctg.1	1529	113.7	1	SNP	p	R228S	1	.	.	682	684	AGC	988	990	AGC	180;181;185	A;G;C,T	179;180;183,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5096	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3328	151.2	1	SNP	p	S91F	0	.	.	271	273	TCC	582	584	TCC	181;185;188	T;C;C,A	179;184;186,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5096	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3328	151.2	1	SNP	p	D95N	0	.	.	283	285	GAC	594	596	GAC	185;184;186	G;A;C	183;180;186	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5096	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3328	151.2	1	SNP	p	D95G	0	.	.	283	285	GAC	594	596	GAC	185;184;186	G;A;C	183;180;186	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1446	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1334	106.9	0	.	p	.	0	A39T	NONSYN	115	117	GCC	469	471	ACC	138;140;141	ACC,ACCC;C;C	131,1;137;137	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1446	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1334	106.9	0	.	p	.	0	R44H	NONSYN	130	132	CGC	484	486	CAC	147;147;148	C;A;C	146;139;146	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1446	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1334	106.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	667	669	CAC	167;165;167	C;A;C	161;156;163	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1446	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1334	106.9	1	SNP	p	G45D	0	.	.	133	135	GGC	487	489	GGC	153;157;160	G;G;C	150;152;158	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	730	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1011	71.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2968	149.8	1	SNP	p	D86N	0	.	.	256	258	GAC	598	600	GAC	167;166;172	G;A;C	165;156;169	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2968	149.8	1	SNP	p	S87I	0	.	.	259	261	AGT	601	603	AGT	177;177;178	A;G;T	173;175;171	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2968	149.8	1	SNP	p	S87W	0	.	.	259	261	AGT	601	603	AGT	177;177;178	A;G;T	173;175;171	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2968	149.8	1	SNP	p	S87R	0	.	.	259	261	AGT	601	603	AGT	177;177;178	A;G;T	173;175;171	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2968	149.8	1	SNP	p	S88P	0	.	.	262	264	TCC	604	606	TCC	176;175;172	T;C;C	171;169;168	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3956	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2781	140.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1600	1602	GGC	187;187;184	G;G;C	186;184;182	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1294	1296	GCA	210;211;211	G,T;C;A	205,2;204;207	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1297	1299	ATC	211;211;213	A;T;C	207;203;205	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1309	1311	GTG	217;219;218	G;T,C;G	212;209,1;213	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1309	1311	GTG	217;219;218	G;T,C;G	212;209,1;213	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1813	1815	ACC	168;169;170	A;C;C	161;167;166	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1867	1869	GCG	164;161;162	G;C,G;G,C	155;142,2;151,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1867	1869	GCG	164;161;162	G;C,G;G,C	155;142,2;151,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1990	1992	GGC	110;107;106	G;G;C	105;104;101	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1999	2001	GGC	100;99;98	G;G;C,T	96;96;92,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	149.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2017	2019	CCG	67;68;69	C;C;G,C	61;62;56,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5050	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3188	157.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1634	1636	CTG	171;170;169	C;T;G	160;159;161	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2378	porA	1146	1146	99.83	porA.l6.c30.ctg.1	2004	116.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	639	639	C	163	C,G	148,3	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	382	384	GGA	211;214;217	G;G;A	206;212;214	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	643	645	CTT	184;186;184	C;T;T	182;184;182	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	667	669	GGA	186;185;190	G;G;A	186;184;183	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	805	807	AGC	192;188;187	A;G,T;C	188;184,1;183	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	0	.	p	.	0	T206_K207insWH	INS	616	616	A	856	856	A	181	A	176	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	877	877	T	179	T	176	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	1	SNP	p	G120K	0	.	.	358	360	GGT	598	600	GGT	202;203;199	G,A;G;T	195,1;201;188	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	1	SNP	p	A121N	0	.	.	361	363	GCC	601	603	GCC	199;199;203	G;C,A;C	196;196,1;199	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2528	porB1b	1035	1035	95.37	porB1b.l15.c17.ctg.1	1441	172.4	1	SNP	p	A121D	0	.	.	361	363	GCC	601	603	GCC	199;199;203	G;C,A;C	196;196,1;199	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9038	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4924	181.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2013	2015	AAT	191;193;193	A;A;T	189;189;189	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	974	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1033	93.5	1	SNP	p	V57M	1	.	.	169	171	ATG	574	576	ATG	185;186;188	A;T;G	183;181;185	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
